This article is more than 5 years old. Information may no longer be current.

Early phase 1 data positive for volociximab-ranibizumab combination

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FORT LAUDERDALE, Fla. — Volociximab, an alpha-5 beta-1 integrin antagonist, combined with ranibizumab treatments for wet age-related macular degeneration is showing a favorable safety profile in early phase 1 studies, according to a poster presentation here.

Baruch D. Kupperman, MD, and colleagues reported at the Association for Research in Vision and Ophthalmology meeting on completed dose escalation results for 10 subjects enrolled in the study.

Patients received three monthly intravitreal injections of volociximab (Ophthotech) in treatment-naïve eyes at one of three doses. Up to six subjects received either 0.5 mg, 1.25 mg or 2.5 mg doses in ascending order combined with Lucentis (ranibizumab, Genentech) .

"Dose escalation was completed without evidence of dose-limiting toxicity or drug-related adverse events," Dr. Kupperman said in the poster.

"Results to date ... suggest that volociximab has a favorable safety profile, and preliminary data supports the preclinical studies," he said.